I Hate Dialysis Message Board
Welcome, Guest. Please login or register.
April 20, 2014, 07:00:01 AM

Login with username, password and session length
Search:     Advanced search
478361 Posts in 29464 Topics by 9054 Members
Latest Member: Jules71
* Home Help Search Login Register
+  I Hate Dialysis Message Board
|-+  Dialysis Discussion
| |-+  Dialysis: News Articles
| | |-+  Can We Improve the Quality of Life for Dialysis Patients?
0 Members and 1 Guest are viewing this topic. « previous next »
Pages: [1] Go Down Print
Author Topic: Can We Improve the Quality of Life for Dialysis Patients?  (Read 3722 times)
okarol
Administrator/Owner
Member for Life
*****
Offline Offline

Gender: Female
Posts: 100244


Jenna - after Disneyland

WWW
« on: November 28, 2009, 05:54:44 PM »

Volume 54, Issue 6, Pages 993-995 (December 2009)

Can We Improve the Quality of Life for Dialysis Patients?

Alan S. Kliger, MDCorresponding Author Informationemail address, Fredric O. Finkelstein, MD

Refers to article:
Association Between Achievement of Hemodialysis Quality-of-Care Indicators and Quality-of-Life Scores , 27 September 2009
Eduardo Lacson, Jianglin Xu, Shu-Fang Lin, Sandie Guerra Dean, J. Michael Lazarus, Raymond Hakim
American Journal of Kidney Diseases
December 2009 (Vol. 54, Issue 6, Pages 1098-1107)
Abstract | Full Text | Full-Text PDF (428 KB)
Article Outline

• Acknowledgment

• References

• Copyright

Related Article, p. 1098

Quality of life (QoL), an individual's perception of his or her life and sense of well-being in relation to his or her goals, expectations, standards, and concerns,1 may be profoundly altered by chronic disease. A recent prospective evaluation of health-related QoL (HRQoL) in a cohort of patients with chronic kidney disease (CKD) showed decreasing scores with advancing CKD.2 Several studies of dialysis patients have shown that measures of HRQoL and depression are correlated with mortality and hospitalization.3, 4, 5, 6 For many dialysis patients, the quality of their lives is more important than hospitalization or mortality rates. Do our treatments with dialysis machines, medications, diet, and lifestyle counseling improve our patients' QoL? To answer this question, we need reliable tools to measure QoL and interventional studies to examine the effect of our treatments on these important outcomes.

The Centers for Medicare & Medicaid Services (CMS) has become increasingly aware of the importance of HRQoL, naming QoL measurement as 1 of 26 quality measures all end-stage renal disease facilities will be required to measure and submit for 100% of their patient population when its CROWNWeb database is operational.7 The new Conditions for Coverage governing dialysis facility operations require that a standardized mental and physical assessment tool be used to measure psychosocial status at regular intervals. Several tools have been used to assess QoL. The KDQoL-36 assessment survey is the tool endorsed by the National Quality Forum. This tool includes both kidney disease–specific and generic questions derived from the Kidney Disease Quality of Life Short Form Questionnaire (KDQoL-SF) and has been widely accepted and used for dialysis patients. Although this measure and others have been used to assess QoL, no measure has achieved the scientific rigor of a gold standard. The Food and Drug Administration (FDA) reviewed published QoL measures used in assessing the efficacy of erythropoiesis-stimulating agents (ESAs) and found them wanting. On September 11, 2007, the Cardiovascular and Renal Drugs Advisory Committee of the FDA expressed concern about the methods used to examine the effect of ESAs on QoL in the published literature. The FDA then removed QoL claims in the previous labeling for ESAs used to treat patients with CKD.8 The FDA currently is devising final guidelines for the use of patient-reported outcomes as important QoL assessment tools. Still, we can learn about the relationship of our treatment to QoL using widely utilized measurement tools, such as the 36-Item Short Form Health Survey (SF-36) and the KDQoL.

In this issue of the American Journal of Kidney Diseases, Lacson et al9 show an association between achievement of quality goals for hemodialysis patients and QoL scores using the SF-36.9 Although previous studies have shown a relationship between achieving quality indicators and mortality, none has previously explored the relationship between these quality goals and patient-reported QoL. This large cross-sectional observational study shows that patients achieving serum albumin, hemodialysis adequacy, and catheter goals had higher Physical and Mental Component Summary scores on the SF-36 questionnaire. Patients who did not achieve targeted hemoglobin (Hb) and phosphorus levels also had lower Physical and Mental Component Summary scores. Incremental achievement of up to 5 goals was associated with progressively higher QoL scores. The reasons for this association deserve further exploration. One interpretation could be that when patients and their health team work together to achieve goals of care previously associated with better survival, they also achieve better patient-perceived QoL. Alternatively, it could be argued that patients with better QoL scores are less ill or more likely to adhere to their treatment regimen and thus more readily achieve targeted treatment goals. For example, patients with clinical depression adhere less to treatment regimens and have lower QoL scores.10

Some of the 5 goals tracked by Lacson et al9 have been relatively easy to achieve. Dialysis adequacy measured using Kt/Vurea and Hb levels increased progressively in the United States in the decade since they were monitored and publicly reported by the CMS.11 In 2008, 94% of US hemodialysis patients had single-pool Kt/Vurea ≥ 1.2 and only 5.9% had significant anemia with an Hb level < 10 g/dL.12 Recent studies have raised concerns that targeted Hb levels > 13 g/dL increase mortality for dialysis patients and those with earlier stages of CKD.13, 14 One of the major reasons to correct anemia has been to improve QoL. In the present study, most QoL domain scores continued to increase with Hb levels ≥ 13 g/dL, albeit not with statistical significance for patients with Hb levels > 13 g/dL. This finding may be particularly important as the “ideal” Hb goal is refined. Others have noted that the most dramatic changes in QoL measures occur as Hb levels are increased to the 11-12-g/dL range.15

Achieving other goals, such as albumin and phosphorus levels, are more challenging. Albumin is a marker of both nutrition and inflammation, and efforts to increase albumin levels using dietary counseling and supplements have been successful only infrequently.16, 17, 18 Phosphorus level control has remained problematic, with only 53% of US dialysis patients achieving phosphorus levels of 3.5-5.5 mg/dL.12 Efforts to improve phosphate control for hemodialysis patients include increasing the duration of dialysis19 and modifying education programs for patients concerning the importance of adherence to dietary and medication regimens. New educational programs for patients incorporating new techniques, such as motivational interviewing,20 may prove to be more successful to achieve these targets. Engaging patients in collaborative explorations of their behavior patterns using reflective listening, acknowledgement, and exploration may enhance patients' motivation to implement changes in their patterns and actively participate in the management of their complex medical regimens.

As Lacson et al9 note, their observational study only defines associations, but does not prove causation. Although many case-mix variables were accounted for in the analysis, socioeconomic, environmental, and geographic factors; comorbid conditions; patient lifestyle; and other factors were not examined in this study. Thus, future studies must prospectively examine not only the effect of achieving goals of treatment on HRQoL, but also the effect of QoL itself on achieving treatment goals. Despite the limitations of an observational study design, this study of a large hemodialysis patient population is an important step in our understanding of how we might improve QoL for dialysis patients.
Acknowledgements
return to Article Outline

Financial Disclosure: None.
References
return to Article Outline

1. 1Sloan JA, Cella D, Frost M, Guyatt GH, Sprangers M, Symonds T. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc. 2002;77:367–370. MEDLINE | CrossRef

2. 2Mujais SK, Story K, Brouillette J, et al. Health-related quality of life in CKD patients: correlates and evolution over time. Clin J Am Soc Nephrol. 2009;4:1293–1301.

3. 3DeOreo PB. Hemodialysis patient-assessed functional health status predicts continued survival, hospitalization, and dialysis-attendance compliance. Am J Kidney Dis. 1997;30:204–212. Abstract | Full-Text PDF (866 KB) | MEDLINE | CrossRef

4. 4Kalantar-Zadeh K, Kopple JD, Block G, Humphreys MH. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol. 2001;12:2797–2806. MEDLINE

5. 5Lowrie EG, Curtin RB, LePain N, Schatell D. Medical Outcomes Study Short Form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients. Am J Kidney Dis. 2003;41:1286–1292. Abstract | Full Text | Full-Text PDF (52 KB)

6. 6Mapes DL, Lopes AA, Satayathum S, et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int. 2003;64:339–349. MEDLINE | CrossRef

7. 7Phase III ESRD Clinical Performance Measures in effect April 1, 2008. http://www.cms.hhs.gov/CPMProject/Downloads/ESRDPhaseIIICPM0401/2008Final.pdfAccessed October 12, 2009..

8. 8FDA Alert (Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126481.htmAccessed October 12, 2009..

9. 9Lacson E, Xu J, Lin SF, Dean SG, Lazarus JM, Hakim R. Association between achievement of hemodialysis quality-of-care indicators and quality-of-life scores. Am J Kidney Dis. 2009;54:1098–1107. Abstract | Full Text | Full-Text PDF (428 KB) | CrossRef

10. 10Hedayati SS, Finkelstein FO. Epidemiology, diagnosis, and management of depression in patients with CKD. Am J Kidney Dis. 2009;54:741–752. Full Text | Full-Text PDF (432 KB) | CrossRef

11. 11Centers for Medicare & Medicaid Services. 2007 Annual Report, End Stage Renal Disease Clinical Performance Measures Project. Baltimore, MD: Department of Health and Human Services, Centers for Medicare & Medicaid Services, Office of Clinical Standards & Quality; December 2007;.

12. 12Elab 2008 and Trends Report, ESRD CPM Data Elements Approved by CMS, Renal Network of the Upper Midwest, St Paul, MN, June 2009. www.esrdnet11.org/Elab/elab_national_2008_and_trends_report.pdfAccessed September 21, 2009..

13. 13Drueke TB, Locatelli F, Clyne N, et al.CREATE Investigators Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084. CrossRef

14. 14Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098. CrossRef

15. 15Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75:15–24. CrossRef

16. 16Kaysen GA, Chertow GM, Adhikarla R, Young B, Ronco C, Levin NW. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int. 2001;60:333–340. MEDLINE | CrossRef

17. 17Kliger AS. Serum albumin measurement in dialysis patients: should it be a measure of clinical performance?. J Ren Nutr. 2002;12:145–147. Full Text | Full-Text PDF (36 KB) | MEDLINE | CrossRef

18. 18Lacson E, Ikizler TA, Lazarus JM, Teng M, Hakim RM. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs. J Ren Nutr. 2007;17:363–371. Abstract | Full Text | Full-Text PDF (511 KB)

19. 19Troidle M, Hotchkiss M, Finkelstein F. A thrice weekly in-center nocturnal hemodialysis program. Adv Chronic Kidney Dis. 2007;14:244–248. Abstract | Full Text | Full-Text PDF (69 KB) | MEDLINE | CrossRef

20. 20Emmons KM, Rollnick S. Motivational interviewing in health care settings (Opportunities and limitations). Am J Prev Med. 2001;20:68–74. Abstract | Full Text | Full-Text PDF (135 KB) | MEDLINE | CrossRef

Yale University School of Medicine, New Haven, Connecticut

Corresponding Author InformationAddress correspondence to Alan S. Kliger, MD, Department of Medicine, Hospital of Saint Raphael, New Haven, CT 06511

PII: S0272-6386(09)01189-5

doi:10.1053/j.ajkd.2009.09.005

http://www.ajkd.org/article/PIIS0272638609011895/fulltext
Logged


Jenna is our daughter, bad bladder damaged her kidneys.
Was on in-center hemodialysis 2003-2007.
TRANSPLANT FROM LIVING DONOR 1/16/07!
Now needs a new kidney, loss due to rejection.
Started PD Sept. 2013
Searching for a living donor using social media, friends, family.
Her story ---> https://www.facebook.com/WantedKidneyDonor
Jenna is an artist, she loves music, is a fan of ComicCon, and has been writing stories since she was little.
Here's her bio on Living Kidney Donor Search http://www.livingkidneydonorsearch.com/our-stories2/jenna-franks2/
Please watch her video: http://youtu.be/D9ZuVJ_s80Y
Living Donors Rock! http://www.livingdonorsonline.org -
News video: http://www.youtube.com/watch?v=J-7KvgQDWpU
Pages: [1] Go Up Print 
« previous next »
 

Powered by MySQL Powered by PHP SMF 2.0.5 | SMF © 2013, Simple Machines
Enotify by CreateAForum.com
Valid XHTML 1.0! Valid CSS!